Spermosens AB (SPERM.ST)
SEK 0.01
(-8.7%)
SEK 0.01
(-8.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -10.7 Million SEK | 13.88% |
| 2022 | -19 Million SEK | -102.47% |
| 2021 | -6.15 Million SEK | -201.22% |
| 2020 | -2.04 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.64 Million SEK | -86.65% |
| 2024 Q2 | -2.04 Million SEK | 21.45% |
| 2024 Q3 | -2.08 Million SEK | -3.83% |
| 2023 FY | - SEK | 13.88% |
| 2023 Q4 | -1.48 Million SEK | 46.28% |
| 2023 Q2 | -3.35 Million SEK | -3.39% |
| 2023 Q1 | -3.24 Million SEK | -5.15% |
| 2023 Q3 | -2.76 Million SEK | 17.63% |
| 2022 Q4 | -3.08 Million SEK | 2.15% |
| 2022 Q3 | -3.15 Million SEK | 14.68% |
| 2022 Q2 | -3.7 Million SEK | -47.53% |
| 2022 Q1 | -2.5 Million SEK | -84.68% |
| 2022 FY | - SEK | -102.47% |
| 2021 Q1 | -885 Thousand SEK | 38.58% |
| 2021 Q4 | -1.35 Million SEK | 30.47% |
| 2021 FY | - SEK | -201.22% |
| 2021 Q3 | -1.95 Million SEK | 0.15% |
| 2021 Q2 | -1.95 Million SEK | -121.02% |
| 2020 Q3 | -485 Thousand SEK | -212.9% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q2 | -155 Thousand SEK | 0.0% |
| 2020 Q4 | -1.44 Million SEK | -197.11% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AroCell AB (publ) | -13.75 Million SEK | 22.204% |
| Devyser Diagnostics AB (publ) | -43.8 Million SEK | 75.562% |
| Immunovia AB (publ) | -166.55 Million SEK | 93.573% |
| Prostatype Genomics AB (publ) | -38.02 Million SEK | 71.846% |
| SenzaGen AB | -13.53 Million SEK | 20.922% |